46 results
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
25 Apr 24
Virax Biolabs Launches Portfolio of Immune Profiling Solutions Evaluating Adaptive Immunity in Post-Viral Syndromes at ESCMID Global 2024
8:03am
2024
LONDON, April 25, 2024 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company … is an innovative biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Virax Biolabs Group Limited
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
16 Apr 24
Virax Biolabs Group Limited to Participate at ESCMID Global 2024
7:34am
(NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral … allowing for remote and face-to-face opportunities.
About Virax Biolabs Group Limited.
Virax Biolabs Group Limited is an innovative biotechnology
6-K
EX-99.1
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
15 Mar 24
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
4:32pm
/PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune … “VRAX.”
About Virax Biolabs Group Limited.
Virax Biolabs Group Limited is an innovative biotechnology company focused on the detection of immune
424B5
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
22 Jan 24
Prospectus supplement for primary offering
5:27pm
and has been operating since 2013.
Virax Cayman and its subsidiaries is a global innovative biotechnology company focused on the prevention, detection … innovative biotechnology company focused on the prevention, detection, diagnosis, and risk management of viral diseases with a particular interest
6-K
EX-99.2
VRAX
Virax Biolabs Group Ltd - Ordinary Shares
12 Jan 24
Current report (foreign)
7:43am
Biolabs Group Limited and its subsidiaries is a global innovative biotechnology company focused on the prevention, detection, diagnosis, and risk
6-K
EX-99.1
zwmx7u7u
12 Jan 24
Current report (foreign)
7:43am
6-K
EX-99.1
0jje9df
21 Dec 23
Current report (foreign)
7:34am
424B3
8esnky6 viy6k0k6
20 Dec 23
Prospectus supplement
4:03pm
6-K
EX-99.1
q3byut
18 Dec 23
Virax Biolabs’ CEO James Foster Issues Letter to Shareholders
7:37am
6-K
EX-99.1
pifxc0gp3fifn7 fj0tv
14 Dec 23
Virax Biolabs Group Limited Announces 1-for-10 Share Consolidation
7:43am
F-3
z70t74ssk
5 Dec 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.1
d2yeid
12 Sep 23
Virax Biolabs Group Announces Early-Access Program Launch of Research Use Only ViraxImmune Product and Hosts Webinar
7:49am
6-K
EX-99.1
w0bwn92c74g3
1 Sep 23
Virax Biolabs Group Appoints Dr. Nigel McCracken as Chief Operating Officer to Oversee Growth Momentum
7:37am
6-K
EX-99.1
kvsft6
3 Aug 23
Nasdaq Approves 180-Day Extension for Virax Biolabs Group to Meet Minimum $1 Bid
8:39am
6-K
EX-99.1
6qhz7ah8bqg189 wux
18 Jul 23
Virax Biolabs Group Continues Growth and Expansion with the Addition of Research and Laboratory Facilities
7:58am
6-K
EX-99.1
4trs92j
14 Jun 23
Virax Biolabs' CEO James Foster Issues Letter to Shareholders
8:00am
6-K
EX-99.1
1swgzs6p jv
4 May 23
Virax Biolabs Group Announces Establishment of Regional Headquarters at Dubai Science Park
7:56am
6-K
EX-99.1
33pqq 3o171bj9f
19 Apr 23
Virax Biolabs Group Limited Has Entered into an Agreement for the Distribution of Marburg Virus PCR Testing Kits
8:32am
424B3
fcs0d15zxq084 limzcx
31 Mar 23
Prospectus supplement
4:04pm